drugset / Trial / NCT06957327

A Study of ERAS-601 in People With Chordoma

NCT06957327

Phase 1/2 Active not recruiting 12 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.

Timeline

Start
2025-04-25
Primary completion
2027-04
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ERAS-601 Unknown 40 mg

Indications